Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis
Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants a...
Saved in:
| Published in | The Lancet (British edition) Vol. 388; no. 10047; pp. 881 - 890 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
27.08.2016
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0140-6736 1474-547X 1474-547X |
| DOI | 10.1016/S0140-6736(16)30385-3 |
Cover
| Abstract | Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.
We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.
We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference −0·51, 95% credible interval [CrI] −0·99 to −0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I2 values were 33·21% for efficacy and 0% for tolerability.
When considering the risk–benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.
National Basic Research Program of China (973 Program). |
|---|---|
| AbstractList | Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people. Methods We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023. Findings We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0.51, 95% credible interval [CrI] -0.99 to -0.03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0.31, 95% CrI 0.13 to 0.95) and imipramine (0.23, 0.04 to 0.78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5.49, 1.96 to 20.86; 3.19, 1.01 to 18.70; and 2.80, 1.20 to 9.42, respectively). In terms of heterogeneity, the global I2 values were 33.21% for efficacy and 0% for tolerability. Interpretation When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated. Funding National Basic Research Program of China (973 Program). Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people. We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023. We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference −0·51, 95% credible interval [CrI] −0·99 to −0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I2 values were 33·21% for efficacy and 0% for tolerability. When considering the risk–benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated. National Basic Research Program of China (973 Program). Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people. We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023. We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0·51, 95% credible interval [CrI] -0·99 to -0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I(2) values were 33·21% for efficacy and 0% for tolerability. When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated. National Basic Research Program of China (973 Program). Summary Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people. Methods We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023. Findings We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference −0·51, 95% credible interval [CrI] −0·99 to −0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I2 values were 33·21% for efficacy and 0% for tolerability. Interpretation When considering the risk–benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated. Funding National Basic Research Program of China (973 Program). Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.BACKGROUNDMajor depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.METHODSWe did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0·51, 95% credible interval [CrI] -0·99 to -0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I(2) values were 33·21% for efficacy and 0% for tolerability.FINDINGSWe deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0·51, 95% credible interval [CrI] -0·99 to -0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I(2) values were 33·21% for efficacy and 0% for tolerability.When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.INTERPRETATIONWhen considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.National Basic Research Program of China (973 Program).FUNDINGNational Basic Research Program of China (973 Program). Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people. Methods We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023. Findings We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0·51, 95% credible interval [CrI] -0·99 to -0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the globalI2values were 33·21% for efficacy and 0% for tolerability. Interpretation When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated. Funding National Basic Research Program of China (973 Program). |
| Author | Whittington, Craig Pu, Juncai Michael, Kurt D Del Giovane, Cinzia Qin, Bin Cohen, David Xie, Peng Leucht, Stefan Ravindran, Arun V Yang, Lining Cuijpers, Pim Coghill, David Liu, Lanxiang Hetrick, Sarah E Cipriani, Andrea Zhang, Yuqing Hazell, Philip Zhou, Xinyu Liu, Yiyun |
| Author_xml | – sequence: 1 givenname: Andrea surname: Cipriani fullname: Cipriani, Andrea email: andrea.cipriani@psych.ox.ac.uk organization: Department of Psychiatry, University of Oxford, Oxford, UK – sequence: 2 givenname: Xinyu surname: Zhou fullname: Zhou, Xinyu organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 3 givenname: Cinzia surname: Del Giovane fullname: Del Giovane, Cinzia organization: Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy – sequence: 4 givenname: Sarah E surname: Hetrick fullname: Hetrick, Sarah E organization: Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia – sequence: 5 givenname: Bin surname: Qin fullname: Qin, Bin organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 6 givenname: Craig surname: Whittington fullname: Whittington, Craig organization: Doctor Evidence, Santa Monica, CA, USA – sequence: 7 givenname: David surname: Coghill fullname: Coghill, David organization: Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK – sequence: 8 givenname: Yuqing surname: Zhang fullname: Zhang, Yuqing organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 9 givenname: Philip surname: Hazell fullname: Hazell, Philip organization: Discipline of Psychiatry, Sydney Medical School, Concord West, NSW, Australia – sequence: 10 givenname: Stefan surname: Leucht fullname: Leucht, Stefan organization: Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany – sequence: 11 givenname: Pim surname: Cuijpers fullname: Cuijpers, Pim organization: Department of Clinical, Neuro- and Developmental Psychology, VU University Amsterdam, Amsterdam, Netherlands – sequence: 12 givenname: Juncai surname: Pu fullname: Pu, Juncai organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 13 givenname: David surname: Cohen fullname: Cohen, David organization: Department of Child and Adolescent Psychiatry, Hôpital Pitié–Salpétrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris, France – sequence: 14 givenname: Arun V surname: Ravindran fullname: Ravindran, Arun V organization: Department of Psychiatry, University of Toronto, Toronto, ON, Canada – sequence: 15 givenname: Yiyun surname: Liu fullname: Liu, Yiyun organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 16 givenname: Kurt D surname: Michael fullname: Michael, Kurt D organization: Department of Psychology, Appalachian State University, Boone, NC, USA – sequence: 17 givenname: Lining surname: Yang fullname: Yang, Lining organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 18 givenname: Lanxiang surname: Liu fullname: Liu, Lanxiang organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China – sequence: 19 givenname: Peng surname: Xie fullname: Xie, Peng email: xiepeng973@126.com organization: Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27289172$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkluL1DAYhoOsuAf9CUrAm_WimqRt0ioqMniCBS9U8C58k37BzLbJbJJZmd_gnzZzWIUB2b1p2vC8T9K8OSVHPngk5DFnzznj8sVXxhtWSVXLcy6f1azu2qq-R054o5qqbdSPI3LyFzkmpyktGGONZO0DciyU6HquxAn5PQvTEiJkd40UrXUGzJqCH2gOI0aYu9HlNQ22zGU34DJiSuU1URsinWBRnvvZjWFwKcQBI3Wemp9uHCL6rQ2GoksGS_IlBeox_wrxkk6YoQIP4zq59JDctzAmfLQfz8j3D--_zT5VF18-fp69u6iMbLpcNSA7tELKvu-NAuRobDu3osNeCc6VtdB2ILmVrRqQ27rvhWQdMCuBg53XZ-R8513GcLXClPXkytbGETyGVdK8E6oXreDqDihXbdspKQr69ABdhFUsv7alCsBKHYV6sqdW8wkHvYxugrjWN40U4NUOMDGkFNFq43KpJ_gcwY2aM73pX2_715tydfna9q_rkm4P0jcL3JZ7u8thOfdrh1En49AbHFxEk_UQ3K2GNwcGMzpfrtN4iWtM_85CJ6HZTrJxcLk1bASv_y-4wwb-APzr8UE |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_3389_fpsyt_2024_1417977 crossref_primary_10_1016_j_biopsych_2020_10_003 crossref_primary_10_1017_S1352465822000662 crossref_primary_10_1111_bcpt_12706 crossref_primary_10_1002_jnr_24732 crossref_primary_10_47671_TVG_77_21_039 crossref_primary_10_1159_000533494 crossref_primary_10_1016_j_prrv_2021_05_001 crossref_primary_10_1089_cap_2022_0090 crossref_primary_10_1016_j_bbi_2023_02_013 crossref_primary_10_3389_fpsyt_2019_00552 crossref_primary_10_1001_jamapsychiatry_2020_2762 crossref_primary_10_1038_s41562_023_01793_5 crossref_primary_10_1089_cap_2017_0077 crossref_primary_10_1177_0004867420979353 crossref_primary_10_1111_caje_12249 crossref_primary_10_1016_j_jos_2017_12_004 crossref_primary_10_1089_cap_2021_0141 crossref_primary_10_1016_j_jaac_2018_06_035 crossref_primary_10_1136_bmjopen_2017_020198 crossref_primary_10_1016_j_ajo_2020_07_046 crossref_primary_10_1089_cap_2021_0027 crossref_primary_10_1024_1422_4917_a000960 crossref_primary_10_1016_j_neubiorev_2022_104717 crossref_primary_10_1113_EP087210 crossref_primary_10_3389_fpsyt_2019_00322 crossref_primary_10_1176_appi_ajp_2020_20060864 crossref_primary_10_3389_fpsyt_2022_878356 crossref_primary_10_1016_j_jad_2020_03_030 crossref_primary_10_1007_s12035_024_04217_1 crossref_primary_10_1016_j_drudis_2023_103804 crossref_primary_10_3389_fphar_2019_01215 crossref_primary_10_4068_cmj_2018_54_2_101 crossref_primary_10_1080_14656566_2023_2199921 crossref_primary_10_1377_hlthaff_2016_0721 crossref_primary_10_1016_j_euroneuro_2020_03_024 crossref_primary_10_1016_j_neuropharm_2022_109208 crossref_primary_10_4306_jknpa_2021_60_3_193 crossref_primary_10_1007_s10571_021_01180_6 crossref_primary_10_1186_s12888_024_05724_0 crossref_primary_10_1016_j_bbr_2016_11_028 crossref_primary_10_2217_pgs_2022_0131 crossref_primary_10_9758_cpn_2021_19_4_751 crossref_primary_10_1002_npr2_12284 crossref_primary_10_1192_bjb_2017_2 crossref_primary_10_1177_0004867416676372 crossref_primary_10_1089_cap_2017_0054 crossref_primary_10_1089_cap_2017_0174 crossref_primary_10_1186_s40814_020_00734_7 crossref_primary_10_1016_S2215_0366_20_30060_2 crossref_primary_10_1016_j_jad_2020_11_039 crossref_primary_10_1016_j_jmig_2017_09_006 crossref_primary_10_1186_s13034_023_00684_x crossref_primary_10_1177_13591045231205004 crossref_primary_10_1016_S2215_0366_19_30215_9 crossref_primary_10_1177_0706743716659276 crossref_primary_10_2147_DDDT_S229145 crossref_primary_10_1002_14651858_CD013674_pub2 crossref_primary_10_1016_j_jpsychires_2021_02_058 crossref_primary_10_1016_j_neurenf_2021_07_005 crossref_primary_10_1136_bmjopen_2021_055796 crossref_primary_10_61164_rsv_v6i1_1821 crossref_primary_10_3389_fpsyt_2021_644741 crossref_primary_10_1089_cap_2017_0060 crossref_primary_10_1080_23727810_2017_1351808 crossref_primary_10_3389_fpsyt_2020_00478 crossref_primary_10_3389_fpsyt_2020_00113 crossref_primary_10_3928_00485713_20191202_01 crossref_primary_10_1016_j_encep_2019_07_014 crossref_primary_10_1136_bmjopen_2017_016608 crossref_primary_10_1016_j_lfs_2020_118582 crossref_primary_10_1007_s00213_020_05699_2 crossref_primary_10_1007_s13311_019_00807_3 crossref_primary_10_1186_s13063_018_2747_8 crossref_primary_10_1016_j_euroneuro_2020_10_008 crossref_primary_10_3390_ijerph19010523 crossref_primary_10_1038_s41398_017_0018_1 crossref_primary_10_1038_s41398_020_01132_6 crossref_primary_10_1111_cns_14614 crossref_primary_10_2139_ssrn_3976033 crossref_primary_10_1016_j_jad_2024_03_111 crossref_primary_10_1016_j_euroneuro_2023_09_006 crossref_primary_10_3389_fpsyt_2020_00017 crossref_primary_10_1080_10543406_2022_2105345 crossref_primary_10_1016_j_neurenf_2022_01_005 crossref_primary_10_1017_S0033291724000539 crossref_primary_10_1186_s13643_021_01627_3 crossref_primary_10_1590_1414_431x20187218 crossref_primary_10_1002_phar_2767 crossref_primary_10_1093_ijnp_pyad047 crossref_primary_10_1002_da_22752 crossref_primary_10_1089_cap_2021_0078 crossref_primary_10_1007_s11920_019_1075_3 crossref_primary_10_3389_fnins_2019_00404 crossref_primary_10_1016_j_jpsychires_2019_02_021 crossref_primary_10_3389_phrs_2022_1604686 crossref_primary_10_1089_cap_2022_0078 crossref_primary_10_1055_a_1215_1638 crossref_primary_10_1097_JCP_0000000000001340 crossref_primary_10_1024_1422_4917_a000954 crossref_primary_10_1176_appi_focus_20220078 crossref_primary_10_1016_j_physbeh_2024_114530 crossref_primary_10_1136_bmjopen_2019_034606 crossref_primary_10_1016_j_med_2017_12_001 crossref_primary_10_1016_j_jpsychires_2025_02_013 crossref_primary_10_1002_brb3_1127 crossref_primary_10_3390_brainsci11040440 crossref_primary_10_1176_appi_focus_20210036 crossref_primary_10_1016_S2215_0366_19_30281_0 crossref_primary_10_3238_arztebl_2020_0261 crossref_primary_10_1016_j_jaac_2017_03_018 crossref_primary_10_1021_acs_chemrestox_0c00411 crossref_primary_10_1016_j_sleep_2018_12_010 crossref_primary_10_1111_jcpp_13262 crossref_primary_10_1007_s00127_019_01714_w crossref_primary_10_1186_s13643_018_0924_1 crossref_primary_10_3389_fpsyt_2019_00705 crossref_primary_10_1001_jamanetworkopen_2021_2373 crossref_primary_10_1038_s43856_021_00046_8 crossref_primary_10_3390_ph17121714 crossref_primary_10_3389_frcha_2024_1364617 crossref_primary_10_1089_cap_2019_0017 crossref_primary_10_1016_j_pnpbp_2020_110036 crossref_primary_10_1016_j_jaac_2022_01_004 crossref_primary_10_1089_cap_2019_0015 crossref_primary_10_1097_WNR_0000000000001101 crossref_primary_10_3389_fpsyt_2023_1147864 crossref_primary_10_1002_14651858_CD013768 crossref_primary_10_1016_j_ejphar_2021_174465 crossref_primary_10_1016_j_jpsychires_2023_06_001 crossref_primary_10_18006_2023_11_3__593_597 crossref_primary_10_1136_eb_2018_102937 crossref_primary_10_1192_bja_2017_21 crossref_primary_10_1016_j_jad_2020_09_058 crossref_primary_10_1186_s40337_017_0153_3 crossref_primary_10_1016_S2215_0366_19_30403_1 crossref_primary_10_1016_S0140_6736_17_32802_7 crossref_primary_10_3389_fpubh_2016_00217 crossref_primary_10_3390_ijerph192316029 crossref_primary_10_1089_cap_2019_0023 crossref_primary_10_1089_cap_2019_0022 crossref_primary_10_1016_j_jad_2018_04_040 crossref_primary_10_1016_j_jad_2022_02_074 crossref_primary_10_1001_jamanetworkopen_2022_27119 crossref_primary_10_1542_peds_2017_2108A crossref_primary_10_1542_peds_2017_2108B crossref_primary_10_1002_wps_20881 crossref_primary_10_1016_j_pnpbp_2020_109946 crossref_primary_10_1016_j_mehy_2020_110337 crossref_primary_10_1002_pds_5358 crossref_primary_10_1016_j_aprim_2020_08_003 crossref_primary_10_1002_wps_20765 crossref_primary_10_1002_wps_20526 crossref_primary_10_1038_s41398_018_0183_x crossref_primary_10_1186_s13034_021_00401_6 crossref_primary_10_1007_s00787_018_1244_7 crossref_primary_10_1016_j_biopsych_2023_06_009 crossref_primary_10_1111_jcpp_12940 crossref_primary_10_1002_14651858_CD013866 crossref_primary_10_1016_j_euroneuro_2016_11_009 crossref_primary_10_1038_s41398_022_01994_y crossref_primary_10_1016_j_jpsychires_2018_07_003 crossref_primary_10_1016_S2215_0366_18_30396_1 crossref_primary_10_1007_s00210_024_03637_z crossref_primary_10_1007_s10517_018_4045_6 crossref_primary_10_1192_bja_2017_3 crossref_primary_10_1111_1556_4029_14684 crossref_primary_10_1002_wps_20631 crossref_primary_10_1038_s41386_021_01214_z crossref_primary_10_3390_children7120268 crossref_primary_10_5498_wjp_v15_i1_100308 crossref_primary_10_1097_NMD_0000000000000749 crossref_primary_10_1016_j_neubiorev_2020_10_014 crossref_primary_10_3390_nu16121953 crossref_primary_10_1016_j_jpsychires_2017_10_018 crossref_primary_10_1016_j_ibneur_2023_12_011 crossref_primary_10_1007_s40261_023_01273_8 crossref_primary_10_5498_wjp_v14_i1_1 crossref_primary_10_3390_children11101246 crossref_primary_10_2174_1381612828666220526150153 crossref_primary_10_3389_fpsyt_2021_674583 crossref_primary_10_1136_ebmental_2018_300040 crossref_primary_10_1016_j_ajp_2023_103838 crossref_primary_10_9758_cpn_2022_20_1_37 crossref_primary_10_1016_j_dcn_2017_04_008 crossref_primary_10_1111_bcp_13604 crossref_primary_10_1016_j_jad_2023_10_151 crossref_primary_10_1176_appi_focus_23021004 crossref_primary_10_1016_S0140_6736_16_30585_2 crossref_primary_10_1080_14656566_2019_1622090 crossref_primary_10_1111_ejn_14757 crossref_primary_10_3389_fpsyt_2022_929207 crossref_primary_10_1007_s11307_023_01825_6 crossref_primary_10_5694_mja2_50383 crossref_primary_10_1038_s41380_018_0047_z crossref_primary_10_1007_s40519_018_0539_5 crossref_primary_10_1089_cap_2017_0160 crossref_primary_10_3389_fpsyt_2019_00764 crossref_primary_10_5888_pcd21_240187 crossref_primary_10_3389_fpsyt_2020_00412 crossref_primary_10_1136_bmjopen_2019_034335 crossref_primary_10_1016_j_pnpbp_2022_110577 crossref_primary_10_1080_14740338_2024_2396396 crossref_primary_10_1590_1516_4446_2020_0935 crossref_primary_10_1080_10503307_2020_1747657 crossref_primary_10_1016_j_jad_2018_06_048 crossref_primary_10_3390_pharmaceutics14122674 crossref_primary_10_1016_j_jaac_2019_10_013 crossref_primary_10_1016_j_ebiom_2018_09_010 crossref_primary_10_1016_j_jare_2023_04_010 crossref_primary_10_3390_ijerph192215403 crossref_primary_10_1016_j_jchromb_2022_123248 crossref_primary_10_3389_fpubh_2024_1431062 crossref_primary_10_1016_j_jtcms_2020_07_009 crossref_primary_10_1016_j_eurpsy_2018_12_008 crossref_primary_10_1016_j_jclinepi_2021_01_015 crossref_primary_10_3390_jpm11111188 crossref_primary_10_1017_S0033291723003306 crossref_primary_10_1007_s00787_024_02560_1 crossref_primary_10_1016_j_mhpa_2020_100338 crossref_primary_10_1371_journal_pone_0232226 crossref_primary_10_1055_a_1302_8108 crossref_primary_10_12968_npre_2016_14_7_324 crossref_primary_10_1038_s41380_021_01306_8 crossref_primary_10_1002_wps_20668 crossref_primary_10_1186_s12888_018_1749_0 crossref_primary_10_3389_fcimb_2021_697640 crossref_primary_10_12968_bjsn_2017_12_10_505 crossref_primary_10_1016_j_jaac_2025_01_006 crossref_primary_10_1186_s13034_020_00316_8 crossref_primary_10_1007_s00127_020_01951_4 crossref_primary_10_1542_peds_2016_1701 crossref_primary_10_1002_ptr_6489 crossref_primary_10_1016_S2352_4642_19_30059_8 crossref_primary_10_1016_S2215_0366_21_00154_1 crossref_primary_10_1017_neu_2021_2 crossref_primary_10_1186_s12888_017_1406_z crossref_primary_10_1136_eb_2017_102701 crossref_primary_10_1007_s11064_018_2591_y crossref_primary_10_1007_s00787_018_01269_2 crossref_primary_10_1089_cap_2018_0145 crossref_primary_10_2196_jmir_8021 crossref_primary_10_1002_jrsm_1452 crossref_primary_10_1007_s43440_022_00420_w crossref_primary_10_3389_fphar_2022_972351 crossref_primary_10_3389_fpsyt_2023_1175002 crossref_primary_10_1007_s00787_018_1189_x crossref_primary_10_1136_eb_2017_102718 crossref_primary_10_2147_JIR_S425780 crossref_primary_10_1007_s15202_017_1598_6 crossref_primary_10_3389_fpsyt_2023_1132791 crossref_primary_10_1016_j_brs_2018_09_007 crossref_primary_10_1016_S2352_4642_22_00316_9 crossref_primary_10_1038_s41386_023_01709_x crossref_primary_10_1016_j_cppeds_2016_11_009 crossref_primary_10_1089_cap_2020_0195 crossref_primary_10_33181_13033 crossref_primary_10_1016_j_cbpra_2018_07_005 crossref_primary_10_1016_j_psychres_2024_115795 crossref_primary_10_1016_j_jaac_2022_03_019 crossref_primary_10_1002_14651858_CD013866_pub2 crossref_primary_10_1016_j_buildenv_2024_112169 crossref_primary_10_1186_s13063_018_2719_z crossref_primary_10_3389_fpsyt_2024_1488260 crossref_primary_10_1016_j_biopha_2019_108853 crossref_primary_10_9758_cpn_2018_16_1_67 crossref_primary_10_1016_j_chc_2018_07_003 crossref_primary_10_1016_j_biopha_2019_108616 crossref_primary_10_1136_dtb_2016_8_0416 crossref_primary_10_1080_14753634_2017_1303786 crossref_primary_10_1002_14651858_CD004052_pub2 crossref_primary_10_1002_da_23064 crossref_primary_10_1016_j_psychres_2017_03_023 crossref_primary_10_1017_S0033291717002653 crossref_primary_10_1186_s12974_021_02097_z crossref_primary_10_3390_brainsci10120992 crossref_primary_10_1093_ageing_afad091 crossref_primary_10_1111_camh_12291 crossref_primary_10_1186_s12875_022_01681_3 crossref_primary_10_1542_peds_2020_0957 crossref_primary_10_3389_fpsyt_2023_1130035 crossref_primary_10_1136_bmjopen_2017_018357 crossref_primary_10_9740_mhc_2018_11_275 crossref_primary_10_1186_s43045_020_00050_z crossref_primary_10_1007_s10578_020_01006_4 crossref_primary_10_3389_fpsyt_2022_930276 crossref_primary_10_1016_j_bbr_2018_12_047 crossref_primary_10_1080_09540121_2020_1719966 crossref_primary_10_1016_j_lfs_2019_116778 crossref_primary_10_1016_j_ejpsy_2021_07_001 crossref_primary_10_1136_bmjopen_2016_013967 crossref_primary_10_1136_dtb_2019_000044 crossref_primary_10_1016_j_conctc_2022_101027 crossref_primary_10_1016_j_jad_2018_08_027 crossref_primary_10_1136_bmjopen_2018_026001 crossref_primary_10_4155_bio_2023_0077 crossref_primary_10_1016_j_jad_2022_11_058 crossref_primary_10_1089_cap_2019_0032 crossref_primary_10_1016_j_psychres_2020_113319 crossref_primary_10_1007_s11682_023_00842_x crossref_primary_10_1016_j_psc_2023_02_007 crossref_primary_10_1186_s40360_023_00664_z crossref_primary_10_1016_j_seizure_2016_10_018 crossref_primary_10_1038_s41380_024_02714_2 crossref_primary_10_1016_j_jad_2020_06_057 crossref_primary_10_1176_appi_ajp_2017_16091059 crossref_primary_10_1371_journal_pone_0200809 crossref_primary_10_3928_00485713_20190509_01 crossref_primary_10_1097_MD_0000000000018611 crossref_primary_10_1024_1422_4917_a001002 crossref_primary_10_1007_s00787_024_02587_4 crossref_primary_10_1111_jphs_12320 crossref_primary_10_1186_s13293_023_00552_5 crossref_primary_10_1155_2024_5448587 crossref_primary_10_3390_pharmaceutics15092202 crossref_primary_10_1016_j_comppsych_2022_152358 crossref_primary_10_1080_1750984X_2020_1833360 crossref_primary_10_1007_s10578_024_01710_5 crossref_primary_10_1136_bmjment_2024_301162 crossref_primary_10_1016_j_neuroscience_2018_02_010 crossref_primary_10_1007_s10578_018_0860_2 crossref_primary_10_1016_j_jad_2021_08_050 crossref_primary_10_1186_s13034_022_00517_3 crossref_primary_10_1017_S1092852917000165 crossref_primary_10_3390_jcm13051222 crossref_primary_10_1016_j_jaac_2018_07_891 crossref_primary_10_1089_cap_2023_0039 crossref_primary_10_3389_fnagi_2022_950143 crossref_primary_10_5093_clysa2020a4 crossref_primary_10_1016_j_bbi_2019_02_001 crossref_primary_10_1176_appi_focus_16407 crossref_primary_10_1016_j_phrs_2024_107085 crossref_primary_10_31682_ayna_870299 crossref_primary_10_1016_j_ynstr_2024_100646 crossref_primary_10_1016_j_jad_2024_01_017 crossref_primary_10_3389_fpsyt_2023_1199510 crossref_primary_10_1016_j_arr_2022_101568 crossref_primary_10_1097_01_JAA_0000000000000003 crossref_primary_10_1186_s12888_022_03760_2 crossref_primary_10_1016_j_jad_2024_01_015 crossref_primary_10_1186_s12887_018_1132_9 crossref_primary_10_3390_ph16071047 crossref_primary_10_1111_jcpp_13202 crossref_primary_10_3390_ijerph18126527 crossref_primary_10_1039_C7CP05688E crossref_primary_10_3389_fpsyt_2018_00187 crossref_primary_10_1080_14740338_2020_1770224 crossref_primary_10_1038_s41598_023_33979_2 crossref_primary_10_1093_ijnp_pyy038 crossref_primary_10_3389_fnsyn_2023_1124112 crossref_primary_10_3390_children10091454 crossref_primary_10_1186_s12888_023_05221_w crossref_primary_10_1002_cpt_3184 crossref_primary_10_12677_ACM_2024_142505 crossref_primary_10_1080_14656566_2018_1445720 crossref_primary_10_3389_fpsyt_2024_1393066 crossref_primary_10_1016_j_biopha_2023_114525 crossref_primary_10_1080_14740338_2018_1475558 crossref_primary_10_1155_2018_4074051 crossref_primary_10_1136_ebmental_2019_300097 crossref_primary_10_1016_j_redox_2025_103491 crossref_primary_10_1371_journal_pmed_1003664 crossref_primary_10_1186_s12916_019_1475_6 crossref_primary_10_1177_2040622320953349 crossref_primary_10_1039_C7RA08726H crossref_primary_10_1192_bjp_2021_128 crossref_primary_10_1111_acps_13001 crossref_primary_10_1542_peds_2017_4082 crossref_primary_10_1186_s13034_019_0296_x crossref_primary_10_3390_life11080765 crossref_primary_10_1016_j_neuropharm_2018_12_020 crossref_primary_10_1016_j_euroneuro_2019_09_601 crossref_primary_10_1186_s13643_020_01568_3 crossref_primary_10_3390_nu15102306 crossref_primary_10_1111_jpc_13503 crossref_primary_10_3389_fphar_2019_00099 crossref_primary_10_1016_j_neuroscience_2018_10_031 crossref_primary_10_1080_0803706X_2022_2097307 crossref_primary_10_3390_ijerph16132255 crossref_primary_10_1016_j_bbih_2021_100396 crossref_primary_10_3390_children10050790 crossref_primary_10_1001_jama_2022_16310 crossref_primary_10_1111_cns_14207 crossref_primary_10_1111_acps_13333 crossref_primary_10_1002_pcn5_231 crossref_primary_10_1186_s13643_023_02447_3 crossref_primary_10_1007_s40279_019_01187_6 crossref_primary_10_1007_s00592_020_01542_4 crossref_primary_10_1016_j_dcn_2016_12_003 crossref_primary_10_1177_0018578720925384 crossref_primary_10_1016_j_ijnurstu_2019_103489 crossref_primary_10_1111_camh_12223 crossref_primary_10_1001_jamapsychiatry_2019_2859 crossref_primary_10_1192_apt_bp_116_016717 crossref_primary_10_1136_bmjopen_2019_036171 crossref_primary_10_3390_ijerph17072393 crossref_primary_10_1080_14740338_2018_1394454 crossref_primary_10_1186_s13098_023_01149_z crossref_primary_10_3389_fpsyt_2020_600283 crossref_primary_10_1371_journal_pmed_1003215 crossref_primary_10_1016_j_bbr_2016_08_001 crossref_primary_10_1016_j_psychsport_2025_102803 crossref_primary_10_1007_s00213_020_05481_4 crossref_primary_10_1177_20406223221098114 crossref_primary_10_1016_j_jad_2018_09_015 crossref_primary_10_1016_j_msard_2024_105763 crossref_primary_10_1016_j_jpha_2022_10_001 crossref_primary_10_1111_gbb_12649 crossref_primary_10_1111_camh_12438 crossref_primary_10_1007_s40272_018_0290_4 crossref_primary_10_1016_j_schres_2020_05_010 crossref_primary_10_1016_j_euroneuro_2019_11_003 crossref_primary_10_3389_fphys_2020_00185 crossref_primary_10_1016_j_semarthrit_2019_06_001 crossref_primary_10_1111_ppe_12870 crossref_primary_10_3389_fpsyt_2019_00170 crossref_primary_10_1016_j_jaac_2020_01_010 crossref_primary_10_1093_ijnp_pyx012 crossref_primary_10_1016_j_jare_2025_03_016 crossref_primary_10_1016_j_neurol_2024_04_005 crossref_primary_10_1002_prp2_355 crossref_primary_10_1097_JCP_0000000000000891 crossref_primary_10_1093_fampra_cmab096 crossref_primary_10_1016_j_jad_2021_07_096 crossref_primary_10_1007_s43440_021_00285_5 crossref_primary_10_1016_S2215_0366_20_30137_1 crossref_primary_10_1038_s41398_022_01969_z crossref_primary_10_1176_appi_neuropsych_20090236 crossref_primary_10_1016_j_jad_2019_02_010 crossref_primary_10_1002_14651858_CD008559_pub3 crossref_primary_10_1016_j_jpsychires_2020_12_043 crossref_primary_10_1007_s15005_016_1898_y crossref_primary_10_1007_s00787_022_02021_7 crossref_primary_10_1007_s00787_020_01492_w crossref_primary_10_1016_j_jpsychires_2024_03_026 crossref_primary_10_4081_ecj_2024_12574 |
| Cites_doi | 10.1177/0004867415617657 10.1192/bjp.bp.106.031088 10.1002/wps.20217 10.1016/j.euroneuro.2016.02.001 10.1136/bmjopen-2015-007768 10.1016/S0140-6736(11)60871-4 10.1016/S0140-6736(09)60046-5 10.1177/0962280207080643 10.1136/bmj.h4320 10.1111/j.1469-7610.2006.01682.x 10.1016/S0140-6736(04)16043-1 10.1371/journal.pone.0076654 10.1016/j.jclinepi.2010.03.016 10.1002/14651858.CD004851.pub3 10.1136/bmj.h824 10.1080/10618600.1998.10474787 10.1371/journal.pone.0099682 10.1001/jamapsychiatry.2013.3074 10.1371/journal.pone.0115065 10.1007/s11999-008-0346-9 10.1371/journal.pone.0009479 10.1002/sim.3767 10.1097/01.chi.0000140453.89323.57 10.1016/S0140-6736(11)61093-3 10.7326/0003-4819-159-2-201307160-00008 10.1001/jamapsychiatry.2015.2955 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Ltd Elsevier Ltd Copyright © 2016 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Aug 27, 2016 |
| Copyright_xml | – notice: 2016 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2016 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Aug 27, 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 |
| DOI | 10.1016/S0140-6736(16)30385-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary Curriculum ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE MEDLINE - Academic ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 890 |
| ExternalDocumentID | 4168667261 27289172 10_1016_S0140_6736_16_30385_3 S0140673616303853 1_s2_0_S0140673616303853 |
| Genre | Comparative Study Network Meta-Analysis Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | National Basic Research Program of China (973 Program). |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 AAYXX ADXHL AGQPQ AGRNS AIGII CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c648t-4a68ef266999c7ae1ecf5bf28e972117ffa58a61f657de1f3992608a0f6a1afb3 |
| IEDL.DBID | 8C1 |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Fri Sep 05 09:13:17 EDT 2025 Fri Sep 05 04:05:45 EDT 2025 Sat Aug 23 12:56:04 EDT 2025 Wed Jul 02 01:57:02 EDT 2025 Tue Jul 01 03:16:40 EDT 2025 Thu Apr 24 22:54:37 EDT 2025 Fri Feb 23 02:34:52 EST 2024 Tue Feb 25 20:08:40 EST 2025 Tue Aug 26 17:21:52 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10047 |
| Language | English |
| License | Copyright © 2016 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c648t-4a68ef266999c7ae1ecf5bf28e972117ffa58a61f657de1f3992608a0f6a1afb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | http://hdl.handle.net/11380/1279478 |
| PMID | 27289172 |
| PQID | 1816230014 |
| PQPubID | 40246 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1827925217 proquest_miscellaneous_1817558762 proquest_journals_1816230014 pubmed_primary_27289172 crossref_citationtrail_10_1016_S0140_6736_16_30385_3 crossref_primary_10_1016_S0140_6736_16_30385_3 elsevier_sciencedirect_doi_10_1016_S0140_6736_16_30385_3 elsevier_clinicalkeyesjournals_1_s2_0_S0140673616303853 elsevier_clinicalkey_doi_10_1016_S0140_6736_16_30385_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-08-27 |
| PublicationDateYYYYMMDD | 2016-08-27 |
| PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2016 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Chaimani, Higgins, Mavridis, Spyridonos, Salanti (bib18) 2013; 8 Brunoni, Tadini, Fregni (bib25) 2010; 5 Tsapakis, Soldani, Tondo, Baldessarini (bib10) 2008; 193 Olfson, Blanco, Wang, Laje, Correll (bib2) 2014; 71 Hopkins, Crosland, Elliott, Bewley (bib4) 2015; 350 (bib7) Oct 15, 2004 Salanti, Del Giovane, Chaimani, Caldwell, Higgins (bib21) 2014; 9 Biau, Kernéis, Porcher (bib23) 2008; 466 Hetrick, McKenzie, Cox, Simmons, Merry (bib8) 2012; 11 Kakuma, Minas, van Ginneken (bib30) 2011; 378 Emslie, Heiligenstein, Hoog (bib28) 2004; 43 (bib13) March, 2011 Dias, Welton, Caldwell, Ades (bib19) 2010; 29 Samara, Dold, Gianatsi (bib26) 2016; 73 Salanti, Ades, Ioannidis (bib20) 2011; 64 Cipriani, Higgins, Geddes, Salanti (bib27) 2013; 159 Cipriani, Furukawa, Salanti (bib14) 2009; 373 Zhou, Qin, Whittington (bib11) 2015; 5 Malhi, Bassett, Boyce (bib5) 2015; 49 Salanti, Higgins, Ades, Ioannidis (bib15) 2008; 17 Thapar, Collishaw, Pine, Thapar (bib3) 2012; 379 Le Noury, Nardo, Healy (bib24) 2015; 351 Costello, Erkanli, Angold (bib1) 2006; 47 Whittington, Kendall, Fonagy, Cottrell, Cotgrove, Boddington (bib9) 2004; 363 Hammad (bib12) 16 August 2004 Bachmann, Aagaard, Burcu (bib6) 2016; 26 Neupane, Richer, Bonner, Kibret, Beyene (bib17) 2014; 9 Cohen (bib22) 1988 Zhou, Hetrick, Cuijpers (bib29) 2015; 14 Brooks, Gelman (bib16) 1998; 7 Brooks (10.1016/S0140-6736(16)30385-3_bib16) 1998; 7 Chaimani (10.1016/S0140-6736(16)30385-3_bib18) 2013; 8 Cohen (10.1016/S0140-6736(16)30385-3_bib22) 1988 Bachmann (10.1016/S0140-6736(16)30385-3_bib6) 2016; 26 Malhi (10.1016/S0140-6736(16)30385-3_bib5) 2015; 49 Cipriani (10.1016/S0140-6736(16)30385-3_bib27) 2013; 159 Zhou (10.1016/S0140-6736(16)30385-3_bib29) 2015; 14 Olfson (10.1016/S0140-6736(16)30385-3_bib2) 2014; 71 Zhou (10.1016/S0140-6736(16)30385-3_bib11) 2015; 5 Salanti (10.1016/S0140-6736(16)30385-3_bib15) 2008; 17 Samara (10.1016/S0140-6736(16)30385-3_bib26) 2016; 73 Le Noury (10.1016/S0140-6736(16)30385-3_bib24) 2015; 351 Whittington (10.1016/S0140-6736(16)30385-3_bib9) 2004; 363 Emslie (10.1016/S0140-6736(16)30385-3_bib28) 2004; 43 Cipriani (10.1016/S0140-6736(16)30385-3_bib14) 2009; 373 Dias (10.1016/S0140-6736(16)30385-3_bib19) 2010; 29 Salanti (10.1016/S0140-6736(16)30385-3_bib21) 2014; 9 Neupane (10.1016/S0140-6736(16)30385-3_bib17) 2014; 9 Costello (10.1016/S0140-6736(16)30385-3_bib1) 2006; 47 Kakuma (10.1016/S0140-6736(16)30385-3_bib30) 2011; 378 Salanti (10.1016/S0140-6736(16)30385-3_bib20) 2011; 64 Brunoni (10.1016/S0140-6736(16)30385-3_bib25) 2010; 5 Hopkins (10.1016/S0140-6736(16)30385-3_bib4) 2015; 350 Hammad (10.1016/S0140-6736(16)30385-3_bib12) Biau (10.1016/S0140-6736(16)30385-3_bib23) 2008; 466 Thapar (10.1016/S0140-6736(16)30385-3_bib3) 2012; 379 Tsapakis (10.1016/S0140-6736(16)30385-3_bib10) 2008; 193 Hetrick (10.1016/S0140-6736(16)30385-3_bib8) 2012; 11 28860137 - Pediatrics. 2017 Sep;140(3):e20172108. doi: 10.1542/peds.2017-2108B. 27289173 - Lancet. 2016 Aug 27;388(10047):844-5. doi: 10.1016/S0140-6736(16)30585-2. |
| References_xml | – volume: 373 start-page: 746 year: 2009 end-page: 758 ident: bib14 article-title: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis publication-title: Lancet – volume: 73 start-page: 199 year: 2016 end-page: 210 ident: bib26 article-title: Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis publication-title: JAMA Psychiatry – volume: 193 start-page: 10 year: 2008 end-page: 17 ident: bib10 article-title: Efficacy of antidepressants in juvenile depression: meta-analysis publication-title: Br J Psychiatry – volume: 9 start-page: e99682 year: 2014 ident: bib21 article-title: Evaluating the quality of evidence from a network meta-analysis publication-title: PLoS One – volume: 363 start-page: 1341 year: 2004 end-page: 1345 ident: bib9 article-title: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data publication-title: Lancet – volume: 14 start-page: 207 year: 2015 end-page: 222 ident: bib29 article-title: Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: a systematic review and network meta-analysis publication-title: World Psychiatry – year: Oct 15, 2004 ident: bib7 article-title: Suicidality in children and adolescents being treated with antidepressant medications – year: March, 2011 ident: bib13 article-title: Cochrane handbook for systematic reviews of interventions (Version 5.1.0) – volume: 9 start-page: e115065 year: 2014 ident: bib17 article-title: Network meta-analysis using R: a review of currently available automated packages publication-title: PLoS One – volume: 8 start-page: e76654 year: 2013 ident: bib18 article-title: Graphical tools for network meta-analysis in STATA publication-title: PLoS One – volume: 7 start-page: 434 year: 1998 end-page: 455 ident: bib16 article-title: General methods for monitoring convergence of iterative simulations publication-title: J Comput Graph Stat – volume: 466 start-page: 2282 year: 2008 end-page: 2288 ident: bib23 article-title: Statistics in brief: the importance of sample size in the planning and interpretation of medical research publication-title: Clin Orthop Relat Res – volume: 379 start-page: 1056 year: 2012 end-page: 1067 ident: bib3 article-title: Depression in adolescence publication-title: Lancet – volume: 64 start-page: 163 year: 2011 end-page: 171 ident: bib20 article-title: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial publication-title: J Clin Epidemiol – volume: 351 start-page: h4320 year: 2015 ident: bib24 article-title: Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence publication-title: BMJ – volume: 5 start-page: e9479 year: 2010 ident: bib25 article-title: Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology publication-title: PLoS One – volume: 159 start-page: 130 year: 2013 end-page: 137 ident: bib27 article-title: Conceptual and technical challenges in network meta-analysis publication-title: Ann Intern Med – volume: 350 start-page: h824 year: 2015 ident: bib4 article-title: Diagnosis and management of depression in children and young people: summary of updated NICE guidance publication-title: BMJ – volume: 17 start-page: 279 year: 2008 end-page: 301 ident: bib15 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res – volume: 49 start-page: 1087 year: 2015 end-page: 1206 ident: bib5 article-title: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders publication-title: Aust N Z J Psychiatry – volume: 26 start-page: 411 year: 2016 end-page: 419 ident: bib6 article-title: Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012 publication-title: Eur Neuropsychopharmacol – volume: 5 start-page: e007768 year: 2015 ident: bib11 article-title: Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis publication-title: BMJ Open – volume: 71 start-page: 81 year: 2014 end-page: 90 ident: bib2 article-title: National trends in the mental health care of children, adolescents, and adults by office-based physicians publication-title: JAMA Psychiatry – volume: 43 start-page: 1397 year: 2004 end-page: 1405 ident: bib28 article-title: Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study publication-title: J Am Acad Child Adolesc Psychiatry – volume: 11 year: 2012 ident: bib8 article-title: Newer generation antidepressants for depressive disorders in children and adolescents publication-title: Cochrane Database Syst Rev – year: 16 August 2004 ident: bib12 article-title: Relationship between psychotropic drugs and pediatric suicidality – volume: 378 start-page: 1654 year: 2011 end-page: 1663 ident: bib30 article-title: Human resources for mental health care: current situation and strategies for action publication-title: Lancet – volume: 29 start-page: 932 year: 2010 end-page: 944 ident: bib19 article-title: Checking consistency in mixed treatment comparison meta-analysis publication-title: Stat Med – year: 1988 ident: bib22 publication-title: Statistical power analysis for the behavioral sciences – volume: 47 start-page: 1263 year: 2006 end-page: 1271 ident: bib1 article-title: Is there an epidemic of child or adolescent depression? publication-title: J Child Psychol Psychiatry – volume: 49 start-page: 1087 year: 2015 ident: 10.1016/S0140-6736(16)30385-3_bib5 article-title: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders publication-title: Aust N Z J Psychiatry doi: 10.1177/0004867415617657 – volume: 193 start-page: 10 year: 2008 ident: 10.1016/S0140-6736(16)30385-3_bib10 article-title: Efficacy of antidepressants in juvenile depression: meta-analysis publication-title: Br J Psychiatry doi: 10.1192/bjp.bp.106.031088 – volume: 14 start-page: 207 year: 2015 ident: 10.1016/S0140-6736(16)30385-3_bib29 article-title: Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: a systematic review and network meta-analysis publication-title: World Psychiatry doi: 10.1002/wps.20217 – volume: 26 start-page: 411 year: 2016 ident: 10.1016/S0140-6736(16)30385-3_bib6 article-title: Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012 publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2016.02.001 – volume: 5 start-page: e007768 year: 2015 ident: 10.1016/S0140-6736(16)30385-3_bib11 article-title: Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis publication-title: BMJ Open doi: 10.1136/bmjopen-2015-007768 – volume: 379 start-page: 1056 year: 2012 ident: 10.1016/S0140-6736(16)30385-3_bib3 article-title: Depression in adolescence publication-title: Lancet doi: 10.1016/S0140-6736(11)60871-4 – volume: 373 start-page: 746 year: 2009 ident: 10.1016/S0140-6736(16)30385-3_bib14 article-title: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(09)60046-5 – volume: 17 start-page: 279 year: 2008 ident: 10.1016/S0140-6736(16)30385-3_bib15 article-title: Evaluation of networks of randomized trials publication-title: Stat Methods Med Res doi: 10.1177/0962280207080643 – volume: 351 start-page: h4320 year: 2015 ident: 10.1016/S0140-6736(16)30385-3_bib24 article-title: Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence publication-title: BMJ doi: 10.1136/bmj.h4320 – ident: 10.1016/S0140-6736(16)30385-3_bib12 – volume: 47 start-page: 1263 year: 2006 ident: 10.1016/S0140-6736(16)30385-3_bib1 article-title: Is there an epidemic of child or adolescent depression? publication-title: J Child Psychol Psychiatry doi: 10.1111/j.1469-7610.2006.01682.x – volume: 363 start-page: 1341 year: 2004 ident: 10.1016/S0140-6736(16)30385-3_bib9 article-title: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data publication-title: Lancet doi: 10.1016/S0140-6736(04)16043-1 – volume: 8 start-page: e76654 year: 2013 ident: 10.1016/S0140-6736(16)30385-3_bib18 article-title: Graphical tools for network meta-analysis in STATA publication-title: PLoS One doi: 10.1371/journal.pone.0076654 – volume: 64 start-page: 163 year: 2011 ident: 10.1016/S0140-6736(16)30385-3_bib20 article-title: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.03.016 – volume: 11 year: 2012 ident: 10.1016/S0140-6736(16)30385-3_bib8 article-title: Newer generation antidepressants for depressive disorders in children and adolescents publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD004851.pub3 – volume: 350 start-page: h824 year: 2015 ident: 10.1016/S0140-6736(16)30385-3_bib4 article-title: Diagnosis and management of depression in children and young people: summary of updated NICE guidance publication-title: BMJ doi: 10.1136/bmj.h824 – volume: 7 start-page: 434 year: 1998 ident: 10.1016/S0140-6736(16)30385-3_bib16 article-title: General methods for monitoring convergence of iterative simulations publication-title: J Comput Graph Stat doi: 10.1080/10618600.1998.10474787 – year: 1988 ident: 10.1016/S0140-6736(16)30385-3_bib22 – volume: 9 start-page: e99682 year: 2014 ident: 10.1016/S0140-6736(16)30385-3_bib21 article-title: Evaluating the quality of evidence from a network meta-analysis publication-title: PLoS One doi: 10.1371/journal.pone.0099682 – volume: 71 start-page: 81 year: 2014 ident: 10.1016/S0140-6736(16)30385-3_bib2 article-title: National trends in the mental health care of children, adolescents, and adults by office-based physicians publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2013.3074 – volume: 9 start-page: e115065 year: 2014 ident: 10.1016/S0140-6736(16)30385-3_bib17 article-title: Network meta-analysis using R: a review of currently available automated packages publication-title: PLoS One doi: 10.1371/journal.pone.0115065 – volume: 466 start-page: 2282 year: 2008 ident: 10.1016/S0140-6736(16)30385-3_bib23 article-title: Statistics in brief: the importance of sample size in the planning and interpretation of medical research publication-title: Clin Orthop Relat Res doi: 10.1007/s11999-008-0346-9 – volume: 5 start-page: e9479 year: 2010 ident: 10.1016/S0140-6736(16)30385-3_bib25 article-title: Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology publication-title: PLoS One doi: 10.1371/journal.pone.0009479 – volume: 29 start-page: 932 year: 2010 ident: 10.1016/S0140-6736(16)30385-3_bib19 article-title: Checking consistency in mixed treatment comparison meta-analysis publication-title: Stat Med doi: 10.1002/sim.3767 – volume: 43 start-page: 1397 year: 2004 ident: 10.1016/S0140-6736(16)30385-3_bib28 article-title: Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study publication-title: J Am Acad Child Adolesc Psychiatry doi: 10.1097/01.chi.0000140453.89323.57 – volume: 378 start-page: 1654 year: 2011 ident: 10.1016/S0140-6736(16)30385-3_bib30 article-title: Human resources for mental health care: current situation and strategies for action publication-title: Lancet doi: 10.1016/S0140-6736(11)61093-3 – volume: 159 start-page: 130 year: 2013 ident: 10.1016/S0140-6736(16)30385-3_bib27 article-title: Conceptual and technical challenges in network meta-analysis publication-title: Ann Intern Med doi: 10.7326/0003-4819-159-2-201307160-00008 – volume: 73 start-page: 199 year: 2016 ident: 10.1016/S0140-6736(16)30385-3_bib26 article-title: Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2015.2955 – reference: 27289173 - Lancet. 2016 Aug 27;388(10047):844-5. doi: 10.1016/S0140-6736(16)30585-2. – reference: 28860137 - Pediatrics. 2017 Sep;140(3):e20172108. doi: 10.1542/peds.2017-2108B. |
| SSID | ssj0004605 |
| Score | 2.6602073 |
| SecondaryResourceType | review_article |
| Snippet | Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this... Summary Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological... Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 881 |
| SubjectTerms | Adolescent Adolescents Amitriptyline - administration & dosage Amitriptyline - adverse effects Antidepressants Antidepressive Agents - administration & dosage Antidepressive Agents - adverse effects Bayes Theorem Child Children Children & youth Citalopram - administration & dosage Citalopram - adverse effects Clomipramine - administration & dosage Clomipramine - adverse effects Confounding Factors, Epidemiologic Depressive Disorder, Major - drug therapy Desipramine - administration & dosage Desipramine - adverse effects Double-Blind Method Drug Administration Schedule Duloxetine Hydrochloride - administration & dosage Duloxetine Hydrochloride - adverse effects Evidence-Based Medicine Fluoxetine - administration & dosage Fluoxetine - adverse effects Heterogeneity Humans Imipramine - administration & dosage Imipramine - adverse effects Internal Medicine Mental depression Mental disorders Meta-analysis Mianserin - administration & dosage Mianserin - adverse effects Mianserin - analogs & derivatives Mirtazapine Nortriptyline - administration & dosage Nortriptyline - adverse effects Paroxetine - administration & dosage Paroxetine - adverse effects Piperazines Randomized Controlled Trials as Topic Research Design Risk assessment Sertraline - administration & dosage Sertraline - adverse effects Studies Systematic review Teenagers Treatment Outcome Triazoles - administration & dosage Triazoles - adverse effects Venlafaxine Hydrochloride - administration & dosage Venlafaxine Hydrochloride - adverse effects |
| Title | Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673616303853 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673616303853 https://dx.doi.org/10.1016/S0140-6736(16)30385-3 https://www.ncbi.nlm.nih.gov/pubmed/27289172 https://www.proquest.com/docview/1816230014 https://www.proquest.com/docview/1817558762 https://www.proquest.com/docview/1827925217 |
| Volume | 388 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT9wwELUKSFUvVenntnTlSj20B5c4iT-WC2pXIFQJVLVF2ps1m9gSCBLKhgO_gT_NTOJkOSzQS6QkfknkcTzP9swzY59BlSEvskQoGwqRW2_ExNpM5OXc4ocTxaZE4cMjfXCc_5ypWZxwW8Swyr5PbDvqsi5ojnwbPRF6amL0uxf_BO0aRaurcQuNNbZBOaA0-LJTuSovsg1xX2bwbP8ZLn6R-mtG62Miu8833cc9Wx-0_4I9j-SRf--svcme-Oole3oYl8dfsZvpUsubexKHgOKaQ1Xypj7zl50k9zWvA15rTmIQLAXCcKSu_BxO8diHxuITyqjMyU8q3id9t0-7IwO1w4FXXSg5P_cNCIgqJ6_Z8f7e3-mBiLstiELnthE5aOsD-mu0T2HAS18ENQ-p9STwI00IoCxoGbQypZeBFG11YiEJGiSEefaGrVd15d8xbvJJaSZoLqRzuYQCgiIx5DRRYND7wYjlfT27IkqR044YZ25FzBmeteZx2Yh9G2AXnRbHYwDdG9H1iabYNTr0Fo8BzSqgX8QffOGkW6Qu6dAERlpLUETaARk5TMdN_uelW307c8v3DM1-xD4Nt7ELoHUdqHx91ZYxSpFbe6gMKUUiVzMj9rZrw0MdpgZH3Uhk3z_8AR_YM2SLmibUU7PF1pvLK_8RGVkzH7M1MzPj9ucbs40fe0e_ft8C0pIxJA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVoJeEO8uFDASSHBwm4dfi1QhKK22tLtC0Eq9GW9iS6A2Kd1UaH8D_4nfxkziZDlsWy69RMpjHMuPmc_2zDeEvLQi9zxLIya0zxjXTrGB1inj-URDxRFiY6DwaCyHh_zTkThaIn_aWBh0q2x1Yq2o8zLDPfINsERgqRHRvzv9yTBrFJ6utik0bEitkG_WFGMhsGPPzX7BEm66ufsR-vtVkuxsH2wNWcgywDLJdcW4ldp5sFNQr0xZF7vMi4lPtENim1h5b4W2MvZSqNzFHplcZaRt5KWNrZ-kUO4NssxxA6VHlj9sjz9_WRSZWTvZz2OINr52D1_H8k2KJ3Qsvcg6XoR-ayu4c4fcDvCVvm_G212y5Ip75OYoHNDfJ7-35mzi1CE9hc1m1BY5rcpjd9aQgs9o6eEZtGPjhouuOBTAMz2xP-DaOudCCXngBqXfC9qGndel_UNE9ZZaWjTO7PTEVZbZwLPygBxeS088JL2iLNwqoYoPcjWAAQOAksc2s14gHXMSCavA_to-4W07myyQoWNOjmOzwOsN7uruMWmfrHdipw0byFUCsu1E04a6gnI2YK-uElSLBN00qJipic00MVEjjcIArFEUJHUnGVBUg47-56dr7Tgz8_90E69PXnSvQQnhyZItXHlef6OEQMN62TfIVQloUfXJo2YMd22YKFj3A5R-fHkFnpNbw4PRvtnfHe89ISuAXSVu7ydqjfSqs3P3FPBhNXkWJiEl36573v8FBUtzHg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouiDdbChgJJDiYzcOvRUIItaxaSiskqLQ343VsqahN2m4qtL-Bf8SvYyZxshy2LZdeIuUxjhWPZz7HM98Q8tKKInCXJ0zo4BjXXrGR1jnjxVRDxxFiY6Lw3r7cPuCfJ2KyQv50uTAYVtnZxMZQF5XDf-RD8ETgqRHRD0MMi_i6Nf5wcsqwghTutHblNFoV2fXzX7B8m73f2YKxfpVl40_fN7dZrDDAnOS6ZtxK7QP4KOiTU9an3gUxDZn2SGqTqhCs0FamQQpV-DQgi6tMtE2CtKkN0xzavUFuqpxzLBuhJmpZTmYTXr_IHhp-6y--TuWbHPfmWH6RX7wI9zb-b3yH3I7AlX5sNe0uWfHlPbK2F7fm75PfmwseceqRmMK6ObVlQevqyJ-1dOBzWgW4Vh_GAFwMwqEAm-mx_QnHLiwXWigiKyg9LGmXcN609g8F1TtqadmGsdNjX1tmI8PKA3JwLePwkKyWVekfE6r4qFAjUBWAkjy1zgaBRMxZIqwCz2sHhHff2bhIg47VOI7Mkng3OGuGx-QD8rYXO2l5QK4SkN0gmi7JFcyyAU91laBaJuhn0bjMTGpmmUlaaRQGSI2iIKl7yYifWlz0Py_d6PTMLN7TT7kBedHfBvODe0q29NV584wSAl3qZc8gSyXgRDUgj1od7r9hpmDFDyB6_fIOPCdrMNvNl5393SfkFoBWif_1M7VBVuuzc_8UgGE9fdbMQEp-XPeU_wvO8nC6 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+efficacy+and+tolerability+of+antidepressants+for+major+depressive+disorder+in+children+and+adolescents%3A+a+network+meta-analysis&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Cipriani%2C+Andrea&rft.au=Zhou%2C+Xinyu&rft.au=Del+Giovane%2C+Cinzia&rft.au=Hetrick%2C+Sarah+E&rft.date=2016-08-27&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.volume=388&rft.issue=10047&rft.spage=881&rft.epage=890&rft_id=info:doi/10.1016%2FS0140-6736%2816%2930385-3&rft.externalDocID=S0140673616303853 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |